trial summary · NCT07197671
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
Phase 1 Study of Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 Therapy for Metastatic Cancer
Trial record from the TrialBase DB dataset, status RECRUITING, condition Metastatic Cancer, sponsored by University of Wisconsin, Madison. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
Source record: https://clinicaltrials.gov/study/NCT07197671
Facts
| registry id | NCT07197671 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Metastatic Cancer |
| sponsor | University of Wisconsin, Madison |
| sponsor class | OTHER |
| enrollment | 60 |
| start date | 2026-11-01 |
| primary completion | 2028-09 |
| completion | 2028-09 |
| results posted | not reported |
Conditions
- Metastatic Cancer
Interventions
- 90Y-NM600
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.